Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucagon and insulin aspart represent a therapeutic combination used in diabetes management. Insulin aspart is a fast-acting insulin analog that helps control blood glucose levels by promoting glucose absorption from the bloodstream. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid, which decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Glucagon works in opposition to insulin, raising blood glucose levels when they fall too low. This combination is particularly important for managing hypoglycemia (low blood sugar) that can occur with insulin therapy. Patients using insulin aspart are often advised to have glucagon available as an emergency treatment for severe hypoglycemic episodes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon + insulin aspart.